Clinical Data Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3 BioSpaceSales of Amgen's thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025.Clinical DataOphthalmologyRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) BioSpace Sales of Amgen’s thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025. Clinical DataOphthalmologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Amgen scores with new thyroid eye disease formulationNext: AI giant Anthropic buys Coefficient Bio for $400m Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
